PNC-27

Developed as a p53-derived peptide analog, PNC-27 has attracted scientific interest due to its structural design and its ability to bind HDM-2 under experimental conditions. Preclinical studies have examined its interactions with membrane-associated HDM-2, peptide-mediated membrane disruption, and molecular processes associated with cancer cell biology. 

Ongoing investigations focus on understanding peptide-membrane interactions, molecular mechanisms associated with tumor cell physiology, and broader applications across oncology, cellular biology, and peptide research.